Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3690 participants.
Also called NCT07625774
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,690 participants
- Registry
-
NCT07625774
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07625774. Randomized; quadruple masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2031-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
- Acronym
- RENEW-CKD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- HRS-7535
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct07625774- Content hash
a0bc837ad800cfebff128982094d748c28d38a0543c97342ade31202d4f08f69